Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
about
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and BeyondDifferential diagnosis of neuromyelitis optica spectrum disorders.A meditation on medications, among other thingsIncomplete Susac syndrome exacerbated after natalizumab.Present and Future Therapies in Neuromyelitis Optica Spectrum DisordersFailure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab.Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.Therapeutic options in neuromyelitis optica spectrum disorders.Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?Pattern Recognition of the Multiple Sclerosis Syndrome.Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.Practice current: How do you treat neuromyelitis optica?[Optical coherence tomography in neuromyelitis optica spectrum disorders].Progressive cerebral atrophy in neuromyelitis optica.Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.Rebound After Fingolimod and a Single Daclizumab Injection in a Patient Retrospectively Diagnosed With NMO Spectrum Disorder-MRI Apparent Diffusion Coefficient Maps in Differential Diagnosis of Demyelinating CNS DisordersDiagnosis and Treatment of NMO Spectrum Disorder and MOG-EncephalomyelitisFunctional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease
P2860
Q26800128-F406739A-80AD-4C89-8170-F2EED19135E0Q33812063-70B9D620-1AED-49B5-A97D-98DB4DE23FE0Q34376438-57114C1A-0D19-451F-8C17-BD82A5EE8D5EQ36092669-5836919A-31F6-4D44-B599-E84F963F6E0AQ36484394-0BE84CCB-B290-4AE5-AFFB-D02726DF935BQ38373789-E145132E-2C13-4595-BEBB-63A01FEC273AQ38610108-9660B3C0-B369-4654-968E-B37404F5A122Q38721559-304EC3CD-065D-4BE3-9AC3-361B7223F9C2Q38816869-707D75D0-E873-4ABA-AFAB-E6BD04130755Q41958613-66A9541D-F962-4FD1-A992-A473112EDB33Q47096340-6C1AFA01-8251-445A-BA87-25C72CDB68C0Q47163794-05B6ADB3-BBE5-4F1C-A1D2-21E2B985F870Q49556620-46655823-65AC-4713-99DE-A5A18201D137Q50101454-20DCEBAD-58E4-4D25-8095-97D3CF68012EQ52149520-DF615C02-4073-41F6-92B8-926759F9481BQ52668258-028EE66E-60F0-4AEF-9AD1-EA319E9DDEC4Q57490936-E6C1DC86-5677-411B-961F-E3234455C48FQ58573155-FFDDE18E-C243-44CA-A66F-724F4B72AECEQ58758199-C96C9E53-B640-4310-BBDB-F173F824AFD8
P2860
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
@ast
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
@en
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
@nl
type
label
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
@ast
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
@en
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
@nl
prefLabel
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
@ast
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
@en
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
@nl
P2093
P2860
P1476
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
@en
P2093
Bruce A C Cree
Jeffrey Klingman
Jeffrey M Gelfand
Jennifer Cotter
P2860
P356
10.1212/NXI.0000000000000034
P50
P577
2014-10-09T00:00:00Z